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Abstract 
 
The MEKK3/MEK5/ERK5 signalling axis is required for cardiovascular development in 
vivo. We analysed the physiological role of ERK5 in cardiac endothelial cells and the 
consequence of activation of this kinase by the statin class of HMG Co-A reductase 
inhibitor drugs. We utilised human microvascular endothelial cells (HCMECs) and altered 
ERK5 expression using siRNA mediated gene silencing or overexpression of 
constitutively active MEK5 and ERK5 to reveal a role for ERK5 in regulating endothelial 
tight junction formation and cell permeability. Statin treatment of HCMECs stimulated 
activation of ERK5 and translocation to the plasma membrane resulting in co-localisation 
with the tight junction protein ZO-1 and a concomitant reduction in endothelial cell 
permeability. Statin mediated activation of ERK5 was a consequence of reduced 
isoprenoid synthesis following HMG Co-A reductase inhibition. Statin pretreatment could 
overcome the effect of doxorubicin in reducing endothelial tight junction formation and 
prevent increased permeability. Our data provides the first evidence for the role of ERK5 
in regulating endothelial tight junction formation and endothelial cell permeability. Statin 
mediated ERK5 activation and the resulting decrease in cardiac endothelial cell 
permeability may contribute to the cardioprotective effects of statins in reducing 
doxorubicin-induced cardiotoxicity. This article is protected by copyright. All rights reserved 
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Introduction 
 
Endothelial cells form a monolayer on the luminal surface of the vasculature providing 
an interface that regulates the transcellular and paracellular passage of solutes and 
xenobiotics between circulation and tissues. Endothelial cell survival and proliferation is 
regulated by mitogen activated protein kinases (MAPKs) (Nithianandarajah-Jones et al., 
2012; Nithianandarajah-Jones et al., 2014). There are 4 major MAPKs: ERK1/2, JNK, 
P38 and ERK5. ERK5 is the least studied of the 4 major MAPKs, sharing 66% sequence 
homology with ERK2. However, ERK5 differs from other MAPKs with its extended C 
terminal tail containing a number of phosphorylation sites and transcriptional activation 
domain (Buschbeck and Ullrich, 2005). The ERK5 signalling axis has been demonstrated 
to be essential for cardiac development; knockout of MEKK3/MEK5/ERK5 in mice is 
embryonically lethal at E9.5 - 10.5 (Hayashi et al., 2004; Wang et al., 2005; Yang et al., 
2000). Importantly, knockout of ERK5 in adult mice leads to increased vascular leakage 
ultimately leading to death within 2-4 weeks (Hayashi et al., 2004). This data shows that 
ERK5 activity is required in adults to preserve vascular integrity. 
 Endothelial junctions regulate the paracellular passage of ions and xenobiotics 
from the circulation to underlying tissues (Gonzalez-Mariscal et al., 2005). Endothelial 
cells express tight, adherens and gap junctions (Dejana et al., 1995). These have been 
demonstrated to vary in isoform expression depending on their anatomical location. Tight 
junctions located within the brain microvasculature contain significantly higher levels of 
claudin 5 than in the glomerular vasculature, reflecting the difference in permeability 
between the vascular beds (Gunzel and Yu, 2013). Zonula occludens-1 (ZO-1) is a tight 
junction protein, which has recently been shown to regulate adherens junctions, 
angiogenesis and endothelial barrier formation (Tornavaca et al., 2015).  The endothelial 
barrier is altered in several diseases including peripheral oedema (Dong et al., 2016), 
stroke, multiple sclerosis and neurodegenerative diseases (Shi et al., 2016). In these 
conditions, changes in endothelial permeability allow water and solutes to permeate to 
underlying tissues, which leads to infiltration of immune cells (Shi et al., 2016). It is 
becoming apparent that anti-cancer drugs are able to induce changes in endothelial 
permeability, which could be an initiating event in drug-induced cardiotoxicity (Cross et 
al., 2015; Dong et al., 2016; Wolf and Baynes, 2006). We have recently shown that the 
anti-cancer drugs doxorubicin and trastuzumab (Herceptin) can adversely affect cardiac 
microvascular endothelial tight junction formation leading to increased drug permeability 
(Wilkinson et al., 2016). 
 ERK5 has been shown to be activated by a number of growth factors in a range 
of cell types (Nithianandarajah-Jones et al., 2012). We have previously shown that in 
endothelial cells, VEGF stimulates ERK5 activity leading to increased cell survival 
(Roberts et al., 2010). Recent data has shown that vasoprotective drugs such as statins, 
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which inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) 
can also activate ERK5 in endothelial cells (Ohnesorge et al., 2010). In addition to their 
ability to lower LDL-cholesterol, statins have several pleiotropic effects such as 
cardioprotection, however the mechanism behind this is not yet fully understood (Chen 
et al., 2013; Henninger et al., 2012; Wang et al., 2008). Statins competitively inhibit HMG-
CoA reductase (Stancu and Sima, 2001) preventing the production of cholesterol as well 
as isoprenoid intermediates such as farnesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphates (GGPP) (Sen-Banerjee et al., 2005). The ability of statins to ameliorate 
drug-induced cardiovascular toxicity has recently been demonstrated in animal models, 
with cardioprotective effects attributed to effects on cardiomyocytes (Henninger et al., 
2015; Yoshida et al., 2009).  
 Here we report that statins activated ERK5 in human cardiac microvascular 
endothelial cells and that this activation results in an increase in tight junction formation 
and decreased permeability; statins can ultimately protect against doxorubicin injury of 
endothelial cells, which may contribute to the cardioprotective effects of these drugs. 
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Materials and Methods 
 
Cell culture 
Human cardiac microvascular endothelial cells (HCMECs, C12285), human dermal 
microvascular endothelial cells (HDMECs, C-12212), human coronary artery endothelial 
cells (HCAECs, C-12221), human brain microvascular endothelial cells (HBMECs, C-
12287), human umbilical vein endothelial cells (HUVECs, C-12205) were purchased from 
PromoCell (Heidelberg, Germany) and cultured as described previously (Wilkinson et al., 
2016). A2780 cells were routinely cultured in RPMI 1640 medium (61870044, Gibco) 
supplemented with 10% (v/v) FCS. BT474 cells were routinely cultured in DMEM medium 
(D6429, Sigma, Poole, UK) supplemented with 10% (v/v) FCS. Cells were incubated at 
37˚C in humidified air containing 5% (v/v) CO2.  
 
Cell stimulation and preparation of cell lysates 
HCMECs were grown to confluence over 6 days in FGM with changes every 2-3 days, 
before addition of drugs. Simvastatin (S6196 purchased from Selleck Chemicals) was 
diluted to 0.3 µM in EBM supplemented with 1% (v/v) FCS and then added to cells for 
6hrs either alone or as a pre-incubation before addition of doxorubicin (S1208, Selleck 
Chemicals) diluted to 0.1 µM for a further 6hrs. BIX02189 (S1531, Selleck Chemicals) 
diluted to 1 µM was added 30 minutes prior to simvastatin treatment.  
 
Cells were washed in ice-cold DPBS on ice followed by addition of RIPA (20 mM Tris pH 
7.5, 150 mM NaCl, 2.5 mM EDTA, 10% (w/v) glycerol, 1% (v/v) Triton X-100; 1 mM 
Na3VO4; 10 µg/ml Aprotinin; 10 µg/ml Leupeptin; 10 µg/ml Pepstatin A; 1 mM PMSF; 
0.5% (v/v) SDS and 0.5% (v/v) sodium deoxycholate) lysis buffer. Lysates were 
centrifuged [17,000 x g for 20 minutes at 4˚C] before diluting in LDS sample buffer 
(Invitrogen, Paisley, UK) containing 2-mercaptoethanol (Sigma, Poole, UK) and 
denaturing at 90˚C for 5 minutes.      
 
Cell Fractionation 
Cellular fraction was performed using a ThermoScientifc subcellular protein fractionation 
kit (78840). In brief, cells were harvested with trypsin-EDTA and centrifuged [500 x g for 
5 minutes]. All buffers contain the protease inhibitor cocktail provided with the kit. The 
cell pellet was washed in ice cold PBS and centrifuged [500 x g for 5 minutes]. The cell 
pellet was resuspended in cytoplasmic extraction buffer (CEB) and incubated on ice for 
10 minutes. Lysates were centrifuged [500 x g for 5 minutes] and the supernatant 
transferred to a new tube for the cytoplasmic fraction. The pellet was resuspended in 
membrane extraction buffer (MEB) and incubated on ice for 10 minutes. Lysates were 
centrifuged [3000  x g for 5 minutes] and the supernatant transferred to a new tube for 
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the membrane fraction. The pellet was resuspended in nuclear extraction buffer (NEB) 
and incubated on ice for 30 minutes. Lysates for centrifuged [5000  x g for 5 minute] and 
the supernatant transferred to a new tube as the nuclear fraction. All fractions were 
diluted with LDS sample buffer containing 2-mercaptoethanol and denatured at 90˚C for 
5 minutes.  
 
Western Blot and Immunoprecipitation 
For immunoprecipitation, lysates were incubated with ERK5 (2 µg/mL, #AF2848, R&D 
systems) or control IgG (2 µg/mL, goat) and protein G agarose. Lysates were separated 
by SDS-PAGE on 8% Tris-glycine gels (8% (w/v) acrylamide, 0.4 M Tris-HCl pH8.8 
0.08% (w/v) SDS, 6.2% (v/v) glycerol 0.05% (v/v) temed and 0.02% (w/v) APS).  Gels 
were resolved for 90 minutes at 35 mA and transferred to 0.2 µm nitrocellulose 
membrane (Hybind-C, GE Healthcare, Amersham, UK) for 2hrs at 125 mA. Membranes 
were blocked in 5% (w/v) bovine serum albumin (BSA) diluted in Tris-buffered saline 
(TBS) with 0.1% (v/v) Tween- 20 (TBST) and probed with primary antibodies, directed 
against: ERK5 (#3372), phospho ERK1/2 (#4370), GAPDH (#5174), phospho ERK5 
(T218/Y220) (#3371), ERK1/2 (#4695) were purchased from New England Biolabs 
(Hitchin, UK). Antibodies to RAP1 (SC-65) and unprenylated RAP1A (SC-1482) were 
purchased from Santa Cruz Biotechnology. Antibodies to MEKK2 (ab33918), MEKK3 
(ab40750) and MEK5 (ab45146) were purchased from Abcam (Cambridge, UK). 
Antibody to ZO-1 (40-2200) was purchased from Invitrogen (Thermo Fisher Scientific). 
All antibodies were diluted in 1% (w/v) BSA and incubated overnight at 4˚C. Proteins 
were detected using rabbit- or goat- specific HRP secondary antibodies (Jackson 
Immunoresearch Labs) and enhanced-chemiluminescence (ECL) western blotting 
detection reagent (Pierce).  
 
Immunofluorescence 
HCMECs were fixed in 2% (w/v) PFA, permeabilised in 0.25% (v/v) triton X-100 (for ZO-
1 and Alexa Fluor® Phalloidin 568 staining). For ERK5 staining cells were fixed in ice-
cold methanol at -20˚C for 10 minutes. Cells were blocked in 1% (w/v) BSA diluted in 
TBST for 1hr.  Primary antibody and Alexa Fluor® secondary antibodies (Invitrogen, 
Thermo Fisher Scientific) were diluted in 1% (w/v) BSA diluted in TBST. Images were 
taken on a Zeiss AxioObserver Z1 inverted fluorescence microscope with Apotome2 
optical sectioning device using an X63/1.25 oil immersion objective.   
 
Trans-endothelial permeability assay 
HCMECs were plated onto ThinCerts™ 0.4 μm translucent (12-well; Greiner, UK) and 
grown to confluence over 6 days. HCMECs were washed in DPBS before addition of 2 
mg/ml FITC-dextran 4 kDa (Sigma, Poole, UK) diluted in phenol red free EBM 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
supplemented with 1% (v/v) FCS for 25 minutes at 37C in a humidified 5% (v/v) CO2 
atmosphere, after which the fluorescence level in the flow through was measured on a 
Varioskan plate reader (Ex 490 nm and Em 525 nm).   
 
Trans-endothelial electrical resistance (TEER) assay 
HCMECs were plated onto ThinCerts™ 0.4 μm translucent (12-well; Greiner, UK) and 
grown to confluence over 6 days. Resistance was measured using a Millicell ERS-2 
voltohmeter (Millipore) and multiplied by the surface area of the insert to determine the 
TEER.   
 
siRNA Transfection 
SiRNA duplexes were prepared as per the manufacturer’s instructions using RNAiMAX 
(Non silencing D-001810-10-05, MEKK2 L-003582-02-0005, MEKK3 L-003301-00-0005, 
MEK5 L-003966-00-0005, ERK5 L-003513-00-0005 smart pools or ERK5 J-003513-08, 
J-003513-10 individual duplexes, Dharmacon, GE Healthcare, UK). HCMECs were 
transfected with 10 nM siRNA diluted in Opti-MEM (Invitrogen, Thermo Fisher Scientific) 
with addition of 0.2% (v/v) Lipofectamine RNAiMAX for 6hrs.  HCMEC were washed in 
DPBS with calcium and magnesium before addition of fresh FGM.  Cells were allowed 
to grow to confluence for a further 6 days, with additional media changes every 2 days.  
 
Adenoviral mediated gene expression 
Constitutively active MEK5 cDNA (MEK5(D) HA-Tag) and ERK5 wild-type cDNA (ERK5 
Flag-Tag) (Roberts et al., 2010) were cloned into the adenoviral vector pAd-DEST 
(Invitrogen). Recombinant adenovirus was generated by transient transfection of 
HEK293A cells and adenovirus purified using the Vivapure column (Sartorius, UK). 
HCMECs were infected with Ad-CA-MEK5 and Ad-ERK5 at a MOI of 10 for 24hrs. 
Following transfection, cells were grown in endothelial FGM until confluent.  
 
Viability assay 
HCMECs, A2780s and BT474s were plated on 96-well gelatin-coated plates and 
maintained at sub confluence for 24hrs. Cells were pre-incubated with 0.3 µM simvastatin 
before addition of doxorubicin (30-0.001 µM) for 72hrs. Cells were lysed in Cell Titer 
Glo® (Promega, UK) as described previously (Wilkinson et al., 2016).   
 
Biochemical addback procedure 
HCMECs were cultured as described previously before addition of Squalene (#S3626), 
cholesterol (#C4951), mevalonolactone (#M4667), geranylgeranyl pyrophosphate 
(GGPP, #G6025) and farnesyl pyrophosphate ammonium salt (FPP, #F6892) 
(purchased from Sigma, Poole, UK), for 24hrs.  
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Quantitative real-time PCR (qRT-PCR) analysis 
Total RNA was extracted from a range of endothelial cells and liver tissue using the 
RNAeasy kit following the manufacturer’s instructions (Qiagen, Crawley, UK). cDNA 
synthesis was performed by reverse transcription of 1 µg total RNA as previously 
described (Wilkinson et al., 2016). Primers: SLCO1B1 forward 5’ 
TTGGAGCTTGGTGGCTTAAT3’; SLCO1B1 reverse 5’ CCAGCACATGCAAAGACAGT 
3’. qRT-PCR was performed as described previously (Wilkinson et al., 2016). Cycle 
threshold (CT) values were determined for each mRNA sample and compared to the 
GAPDH control to determine gene expression changes using the comparative CT (2-ΔΔCT) 
method (Livak and Schmittgen, 2001). 
 
Statistical significance 
This was performed using a one-way analysis of variance (ANOVA) followed by 
Dunnett’s post hoc test using SPSS software. Significant differences between control 
and test groups were evaluated with *P values ≤0.05 and **P values ≤0.01, indicated on 
the graphs. Error bars in graphs and histograms denote ± s.d. (standard deviation).   
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Results 
 
Endothelial tight junction formation is dependent on ERK5 
 
Mouse ERK5 knockout studies have suggested a role for ERK5 in preserving vascular 
integrity (Hayashi et al., 2004). Intercellular tight junctions are critical for endothelial cell 
barrier formation and regulation of paracellular diffusion (Tornavaca et al., 2015).  We 
utilised siRNA-mediated silencing of ERK5 to analyse the localisation of the tight junction 
protein zonula occludens-1 (ZO-1) in human cardiac microvascular endothelial cells 
(HCMECs).  ERK5 silencing resulted in reduced localisation of ZO-1 in tight junctions 
(Fig. 1A) with no apparent effect on actin stress fiber formation analysed by phalloidin 
staining (Fig.1 A). The level of ZO-1 protein did not appear to be affected by ERK5 
silencing (Fig. 1B). Loss of endothelial tight junction formation has been linked with an 
increase in paracellular permeability  (Bazzoni and Dejana, 2004).  Analysis of 
permeability using FITC-labelled dextran (Fig. 1C) revealed that ERK5 silencing resulted 
in an increase in permeability in HCMECs (Fig. 1C). We also analysed permeability by 
measuring  transendothelial electrical resistance (TEER) (Wegener and Seebach, 2014). 
Treatment with ERK5 siRNA resulted in a significant decrease in TEER indicating 
increased permeability (Fig.1D). Taken together, this data suggests that ERK5 regulates 
endothelial tight junction formation and paracellular permeability. 
 We have previously shown that the cardiotoxic drug doxorubicin is able to disrupt 
tight junction formation in HCMECs resulting in increased permeability (Wilkinson et al., 
2016). We used adenoviral mediated gene transduction to express a constitutively active 
MEK5 (CA-MEK5) and ERK5 in HCMECs and analyse effects on tight junction formation 
and permeability. Expression of CA-MEK5 and ERK5 resulted in increased tight junction 
formation and cortical actin staining, which was able to overcome the effects of 
doxorubicin (Fig. 2A).  Increased activation of ERK5 was confirmed by mobility shift on 
western blot analysis (Fig. 2B). Concomitant with the effects on tight junction formation, 
expression of CA-MEK5 and ERK5 also resulted in decreased permeability in HCMECs 
(Fig. 2C); this effect was able to prevent the increased permeability seen with doxorubicin 
treatment. This data shows that increased ERK5 activity stimulates tight junction 
formation and decreases permeability in endothelial cells. 
 
Statins induce ERK5 activation in HCMECs  
 
We have previously reported that VEGF is able to activate ERK5 in endothelial cells and 
regulate endothelial cell survival (Roberts et al., 2010). It has recently been reported that 
statin treatment of cells results in ERK5 activation (Chu et al., 2015; Le et al., 2014). We 
were interested in determining the ability of statins to activate ERK5 in HCMECs.  We 
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initially utilised simvastatin (Zocor) to analyse effects on ERK5 and ERK1/2 in HCMECs.  
Treatment of cells with simvastatin for 6hrs resulted in a dose-dependent activation of 
ERK5 in the absence of ERK1/2 activation (Fig. 3A). To confirm the biochemical effect 
of statins in inhibiting HMG Co-A reductase with a concomitant reduction in cholesterol 
and isoprenoid synthesis, we analysed the prenylation status of the small MW GTP-
binding protein Rap1A by western blotting (Antoine et al., 2010; Sidaway et al., 2004). 
Activation of ERK5 was only observed at time points where Rap1A was unprenylated 
(Fig. 3A). A number of different statins with different pharmacokinetic properties have 
been generated over the last 15 years. Simvastatin is a lipophilic type I statin derived 
from a natural product (Gazzerro et al., 2012).  We also utilised another type 1 statin 
pitavastatin (Livalo) as well as rosuvastatin (Crestor) a more recently developed synthetic 
type II hydrophilic statin (Schachter, 2005). All statins showed dose-dependent activation 
of ERK5, with simvastatin the most potent with an EC50 of 17 nM (Fig. 3 C&D; 
Supplementary Fig. 1). ERK5 is activated by phosphorylation of the T-E-Y motif by the 
upstream kinase MEK5 (MAPKK).  MEK5 is activated by phosphorylation on 
Ser311/Thr315 by MEKK3 or MEKK2 (MAPKKK) (Chao et al., 1999; Sun et al., 2001). In 
order to determine if ERK5 was activated by simvastatin via the canonical pathway we 
utilised siRNA duplexes to silence expression of MEKK2, MEKK3, MEK5 and ERK5. 
Silencing of MEKK3 and MEK5 reduced ERK5 activation as shown by a bandshift and 
phosphorylation of Thr218/Tyr220 (Fig. 3E). Silencing of MEKK2 did not affect simvastatin-
mediated activation of ERK5.  This data suggests that simvastatin treatment activates 
ERK5 in HCMECs via a pathway requiring MEKK3 and MEK5. 
 
Statin induced ERK5 phosphorylation occurs via inhibition of protein 
geranylgeranylation 
 
The previous results showed that simvastatin activation of ERK5 requires at least 6hrs 
pre-incubation and occurs simultaneously with the unprenylation of Rap1A.  Inhibition of 
HMG Co-A reductase by statins leads to a reduction in mevalonate and the synthesis of 
isoprenoid intermediates and ultimately reduced cholesterol synthesis (Surani et al., 
1983) (Fig. 4). In order to determine the biochemical pathway downstream of mevalonate 
reduction which leads to activation of ERK5 we used a series of biochemical add backs 
to determine at which point the effect of simvastatin on ERK5 activation could be 
prevented. Treatment with mevalonolactone, a membrane permeable ester of 
mevalonate (Vamvakopoulos and Green, 2003), prevented simvastatin-stimulated ERK5 
activation (Fig.4B). Treatment with cholesterol and the biochemical precursor squalene 
did not prevent simvastatin mediated activation of ERK5 (Fig.4B). Geranylgeranyl-
pyrophosphate (GGPP) and farnesyl-pyrophosphate (FPP) are two isoprenoids 
generated from mevalonate. Treatment with cell-permeable GGPP prevented 
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simvastatin mediated ERK5 activation whereas treatment with cell permeable FPP had 
no effect (Fig.4B). Taken together, this data suggests that simvastatin activates ERK5 
by suppressing the isoprenylation of proteins via GGPP. To further confirm the role of 
geranylgeranylation we utilised the geranylgeranyltransferase-I inhibitor GGTI-298 (Vogt 
et al., 1996). This inhibitor activated ERK5 in HCMECs after 3hr preincubation (Fig. 4C).  
Furthermore, this inhibitor also stimulated tight junction formation (Fig.4D) and inhibited 
permeability in the HCMECs (Fig. 4E). 
 
Statins stimulate endothelial tight junction formation and decreased permeability 
via ERK5  
 
Our initial data showed that constitutive activation of ERK5 can lead to increased 
endothelial tight junction formation and decreased permeability (Fig. 2 A-C).  Statins have 
been shown to stimulate tight junction formation in human pulmonary artery endothelial 
cells (Chen et al., 2014) and rat brain endothelial cells (Morofuji et al., 2010). We were 
interested in determining if statins were also able to stimulate tight junction formation in 
an ERK5 dependent manner in HCMECs. Immunofluorescence analysis of ZO-1 
localisation and actin stress fibres revealed that treatment of HCMECs with simvastatin 
for 6hrs resulted in increased ZO-1 staining at the cell membrane and redistribution of 
actin stress fibres to form a cortical ring of F-actin (Fig. 5A).  Preincubation with the MEK5 
inhibitor BIX02189 (Tatake et al., 2008) prevented simvastatin-mediated tight junction 
formation and actin reorganisation (Fig. 5A).  The biochemical effect of BIX02189 in 
preventing ERK5 activation by simvastatin was confirmed by western blotting (Fig. 5B). 
Furthermore, the apparent increase in ZO-1 staining at the plasma membrane following 
simvastatin treatment was not due to an increase in ZO-1 protein levels (Fig. 5B).  
 We have demonstrated that simvastatin significantly decreased endothelial 
permeability. This decrease in permeability was prevented by pretreatment with 
BIX02189 (Fig. 5C & D). This data suggests that simvastatin regulated ERK5 activity 
leads to increased tight junction formation and reduced permeability in HCMECs.  We 
next investigated the potential interaction between ZO-1 and ERK5 following simvastatin 
treatment. Immunoprecipitation of ERK5 following simvastatin treatment for 6hrs resulted 
in co-precipitation of ZO-1 (Fig. 5E & F) indicating that ERK5 and ZO-1 can interact 
following simvastatin treatment. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
 
Statin treatment prevents doxorubicin effects on tight junctions and cell 
permeability in HCMECs 
 
Statin treatment has been shown to reduce cardiotoxicity associated with doxorubicin 
treatment in vivo using rodent models (Henninger et al., 2015). We have already shown 
that adenoviral mediated overexpression of ERK5 in HCMECs can stimulate tight 
junction formation and overcome the effects of doxorubicin in HCMECs (Fig. 2 A-C). 
Considering that statins are able to activate ERK5 leading to increased tight junction 
formation, we determined the potential for statin pretreatment to overcome the adverse 
effect of doxorubicin on HCMECs. Pre-treatment with simvastatin prevented doxorubicin-
induced disruption in tight junction formation (Fig. 6A) and the concomitant increase in 
HCMEC permeability (Fig. 6C & D). Simvastatin mediated activation of ERK5 was not 
affected by doxorubicin treatment (Fig. 6B). 
 
Statin treatment stimulates ERK5 translocation to the plasma membrane in 
HCMECs  
 
Activation of ERK5 by phosphorylation on Thr218/Tyr220 residues in the kinase domain is 
thought to result in a conformational change that disrupts a nuclear export signal allowing 
translocation of ERK5 to the nucleus (Gomez et al., 2016; Kondoh et al., 2006) and 
regulation of MEF2 mediated gene expression (Kato et al., 1997). Analysis of ERK5 
translocation by immunofluorescence revealed that in HCMECs, simvastatin stimulated 
significant ERK5 translocation to the plasma membrane, which appeared to show a 
degree of co-localisation with ZO-1 (Fig. 7). This co-localisation was maintained in the 
presence of doxorubicin, but was prevented by the MEK5 inhibitor BIX02189 (Fig.7). 
Analysis of simvastatin-mediated ERK5 activation and translocation by subcellular 
fractionation revealed that increased ERK5 activation was evident in the membrane, 
cytoplasm and nuclear fractions (Fig. 8 A & B) with ERK5 showing increased 
translocation to the membrane (Fig. 8C).   
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Discussion 
 
Endothelial tight junctions maintain vascular integrity and regulate paracellular transport 
of molecules. In this study we show that ERK5 regulates the tight junction adaptor protein 
ZO-1 in endothelial cells.  Pharmacological activation of ERK5 with statins results in 
increased association between ZO-1 and ERK5 at the plasma membrane resulting in 
endothelial tight junction formation and decreased paracellular permeability. This effect 
can overcome both the perturbment of tight junction formation and increased 
permeability with doxorubicin. 
 The ERK5 signalling axis has been shown to play a critical role in maintaining 
vascular integrity in the cardiac circulation with MEKK3/MEK5/ERK5 gene ablation in 
mice resulting in embryonic lethality at E9.5-10.5 (Hayashi et al., 2004; Wang et al., 2005; 
Yang et al., 2000). The use of siRNA mediated gene silencing of ERK5 and 
overexpression of ERK5 in HCMECs revealed that ERK5 regulates the tight junction 
associated protein ZO-1 and cell permeability (Fig. 1 & Fig. 2). This finding was further 
supported by the increase in permeability observed with the MEK5 inhibitor BIX02189 
(Fig. 5 C & D). Gene knockout of ZO-1 is embryonically lethal at E9.5-10.5 with embryos 
displaying defective angiogenesis (Katsuno et al., 2008).  Recent data analysing ZO-1 
function in endothelial cells has shown that ZO-1 is required for endothelial cell barrier 
formation and adherens junction formation (Tornavaca et al., 2015).  Our data provides 
a novel link to explain why loss of ERK5 results in disrupted vascular integrity and 
increased permeability in vivo. 
 Statins have been reported to stimulate a number of pleiotropic effects in 
endothelial cells independent of a reduction in serum cholesterol levels (Liao, 2005; 
Wolfrum et al., 2003). This vascular effect has been attributed in part to stimulation of 
endothelial nitric oxide synthase (eNOS) expression leading to vasodilation (Laufs et al., 
1998). More recent data has shown that statin mediated activation of ERK5 in human 
umbilical vein endothelial cells (HUVECs) leads to induction of Kruppel-like factor 4 
(KLF4) and upregulation of eNOS expression (Ohnesorge et al., 2010). 
 In HCMECs, analysis of the kinetics of simvastatin mediated ERK5 activation 
revealed that activation of ERK5 occurred simultaneously with unprenylation of Rap1A 
(Fig. 3).   This suggests that activation occurs through inhibition of HMG Co-A reductase, 
the pharmacological target of statins. The ability of cell permeable GGPP to prevent 
simvastatin activation of ERK5 (Fig. 4B), suggested that loss of geranylgeranylation of 
specific GTP binding proteins, rather than loss of cholesterol synthesis, was responsible 
for activation of ERK5 in HCMECs. This was further confirmed by the use of the 
geranyltransferase I inhibitor GGTI-298 (Fig. 4C). A number of small GTP-binding 
proteins require prenylation with geranylgeranyl groups to localise to biological 
membranes and allow interaction with downstream signalling molecules.  These GTP-
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binding proteins include Rho, Rac, Cdc42 and  Rap (Takai et al., 2001). Recent data has 
shown that atorvastatin treatment of HUVECs can stimulate endothelial barrier formation 
and also lead to increased cytosolic localisation and activation of Rho, Rac and Cdc42 
(Xiao et al., 2013). Another report has shown that simvastatin treatment of bovine aortic 
endothelial cells (BAECs) can lead to increased activation of Rac (Kou et al., 2009). Our 
data shows that statin activation of ERK5 in HCMECs requires MEKK3 (Fig. 3E). It is 
plausible that inhibition of membrane localisation and activation of small GTP-binding 
proteins leads to activation of MEKK3, MEK5 and ultimately activation and translocation 
of ERK5 to the plasma membrane and interaction with ZO-1 by an as yet undefined 
mechanism. Both simvastatin treatment of HCMECs and overexpression of constitutively 
active MEK5 resulted in ERK5 activation in the absence of ERK1/2 activation. Activation 
of ERK5 with agonists such as EGF in HeLa cells has been reported to result in a nuclear 
localisation of ERK5 and transcriptional regulation (Kondoh et al., 2006). In contrast, in 
HCMECs, simvastatin treatment led to decreased nuclear translocation of ERK5 and 
increased membrane translocation (Fig. 7 & Fig. 8). Statin mediated activation of ERK5, 
which occurs in the absence of other intracellular signalling pathways, such as ERK1/2, 
may allow translocation of ERK5 to the plasma membrane and regulation of tight junction 
formation and endothelial cell permeability. 
 The plasma Cmax for simvastatin is approximately 19-30 nM (Bjorkhem-Bergman 
et al., 2011). Activation of ERK5 occurred at therapeutically relevant concentrations of 
simvastatin (Fig. 3A-C).  We found that within the statin class of drugs, the more lipophilic 
statins simvastatin and pitavastatin were more potent activators of ERK5 than the more 
hydrophilic rosuvastatin.  This may reflect differential uptake of the drugs into HCMECs 
as lipophilic statins can be absorbed by passive diffusion through cell membranes 
(Schachter, 2005),  whereas hydrophilic statins, such as rosuvastatin, have been shown 
to utilise the organic anion transporters (OAT) such as OATP1B1 encoded by the 
SLCO1B1 gene, which is highly expressed in hepatocytes (Niemi et al., 2011). Analysis 
of SLCO1B1 mRNA expression in HCMECs revealed very low expression of these 
transporters compared with liver tissue (Supplementary Fig. 2). Analysis of statin uptake 
into different tissues in rodents has shown that the hydrophilic pravastatin inhibited sterol 
synthesis by 90% in the liver and ileum of rodents but less than 14% in kidney, spleen, 
adrenal, testis, prostate and brain, whereas the lipophilic statins lovastatin and 
simvastatin inhibited this process in all tissues (Koga et al., 1990). 
Recent studies in mice have shown that pretreatment with statins can protect 
against doxorubicin-induced cardiotoxicity (Yoshida et al., 2009). This effect was 
attributed to direct effects on cardiomyocytes in a Rac-dependent manner.  Our data 
would suggest that the protective effect of statins can also occur at the level of the cardiac 
microvasculature via activation of ERK5 and increased tight junction formation with a 
concomitant decrease in cellular permeability of doxorubicin ultimately reducing 
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exposure of cardiomyocytes to this drug.   A clinical study in female breast cancer 
patients has shown that simultaneous use of statins and doxorubicin resulted in reduced 
heart failure compared with doxorubicin alone (Seicean et al., 2012). Analysis of the 
effect of simvastatin on viability in HCMECs exposed to doxorubicin showed a potential 
protective effect in contrast to enhanced toxicity to doxorubicin in A2780 ovarian cancer 
cells and BT474 breast cancer cells (Supplementary Fig. 3).  
 One potential drawback to the clinical use of statins in reducing cardiac vascular 
permeability and reducing cardiotoxicity is the potential reduced delivery of 
chemotherapeutic agent to the tumour, reducing clinical efficacy.  However, an in vivo 
study in mice using three different human tumour xenografts has shown that lovastatin 
potentiates doxorubicin anti-tumour activity whilst reducing doxorubicin-associated 
cardiotoxicity (Feleszko et al., 2000). This would appear to back up our in vitro data. 
Furthermore, it is possible that statin mediated effects in potentially reducing tumour 
vascular permeability and delivery of drug to the tumour are ameliorated due to the 
inherent leakiness of tumour blood vessels compared with normal vasculature (Azzi et 
al., 2013; De Bock et al., 2011). 
 In summary, our data shows that ERK5 regulates tight junction formation and 
permeability in cardiac microvascular endothelial cells.  Statin mediated ERK5 activation 
results in the translocation of ERK5 to the plasma membrane and regulation of tight 
junction formation and decreased endothelial cell permeability. Activation of ERK5 by 
drugs such as statins may have therapeutic potential in alleviating conditions where 
endothelial cell barrier formation is compromised such as drug-induced cardiac injury 
(Wilkinson et al., 2016), arterial hypertension (Laine, 1988), sepsis (Rachoin et al., 2013) 
and diabetic nephropathy (Peng et al., 2013). 
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Figure Legends 
 
Fig. 1. siRNA mediated gene silencing of ERK5 induced HCMEC barrier 
perturbment. HCMEC were transfected with non-silencing or ERK5 siRNA for 6hrs and 
allowed to reach confluence over 5 subsequent days. (A) Immunofluorescence imaging 
of tight junctions (ZO-1, green), actin stress fibres (phalloidin, red) and nuclei (Hoechst, 
blue). Arrows indicate barrier perturbment. Scale bars: 10 µm. Results are from 1 
experiment representative of 3. (B) Western blot of ZO-1, ERK5, ERK1/2 and GAPDH 
levels in HCMECs following siRNA induced ERK5 gene silencing. (C) HCMECs were 
plated on Thincerts™ containing 0.4µm pores and permeability of 4 kDa FITC-dextran 
across the HCMEC monolayer was assessed and compared to untransfected cells, 
(n=4), mean ± s.d. **P≤0.01 compared to untransfected. (D) Assessment of TEER was 
conducted on HCMECs plated on Thincerts™ containing 0.4µm pores, (n=4), mean ± 
s.d. **P≤0.01 compared to untransfected. 
 
 
Fig. 2.  Adenoviral mediated ERK5 expression stimulates HCMEC tight junction 
formation.  HCMEC were transfected with Ad-Control or Ad-CA-MEK5 and Ad-ERK5 for 
24 hours before treatment with doxorubicin 0.1µM for 6hrs. (A) Immunofluorescence 
imaging of HCMEC tight junctions (ZO-1, green), actin stress fibres (phalloidin, red) and 
nuclei (Hoechst, blue). Arrows indicate barrier perturbment. Scale bars: 10 µm. Results 
are from 1 experiment representative of 3. (B) Western blot of ERK5, ERK1/2, phospho 
ERK1/2 and GAPDH levels in HCMECs. FLAG-Tag was used to confirm transfection of 
Ad-ERK5 and HA-Tag was used to confirm transfection of Ad-CA-MEK5. (C) HCMECs 
were plated on Thincerts™ with 0.4µm pores and permeability of 4 kDa FITC-dextran 
across the HCMEC monolayer assessed and compared to Ad-Control (n=4), mean ± s.d. 
*P≤0.05 compared to Ad-Control.  
 
Fig. 3.  Simvastatin stimulates ERK5 phosphorylation in HCMECs.  (A) HCMECs 
were incubated with simvastatin at a range of concentrations for 6hrs. Intracellular 
signalling responses were assessed by western blotting for phosphorylation of ERK5 and 
ERK1/2 using phospho-specific antibodies. Unprenylation of Rap1A was measured as a 
control for simvastatin activity. Total protein was measured for ERK5, ERK1/2 and Rap1. 
(B) HCMECs were incubated with 0.3 µM simvastatin at a range of time points. 
Intracellular signalling responses were assessed by western blotting for phosphorylation 
of ERK5 and ERK1/2 using phospho-specific antibodies. Unprenylation of Rap1 was 
measured as a control for simvastatin activity. Total protein was measured for ERK5, 
ERK1/2 and Rap1. (C) The level of ERK5 band shift following treatment with simvastatin, 
rosuvastatin and pitavastatin was quantified relative to vehicle control. (D) Activation of 
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ERK5 by band shift was determined (EC50 concentration), mean ± s.d. (n=3). (E) HCMEC 
were transfected with siRNA to MEKK2, MEKK3, MEK5 and ERK5 for 6hrs and allowed 
to reach confluence over 5 subsequent days before treatment with 0.1% DMSO or 0.3 
µM simvastatin for 6hrs. Western blot of ERK5, phosphorylated-ERK5, MEKK2, MEKK3, 
MEK5 and GAPDH levels in HCMEC. (F) Quantification of ERK5 band shift (n=3) mean 
± s.d. *P≤0.05 compared to untransfected basal. 
Fig. 4. Statin induced ERK5 phosphorylation occurs via inhibition of protein 
geranylgeranylation 
(A) Summary of the key substrates in the cholesterol biosynthesis pathway.  HCMECs 
were treated with (B) mevalonolactone 50 µM, GGPP 10 µM, FPP 10 µM, squalene 10 
µM or cholesterol 10 µM for 24hrs in the presence and absense of simvastatin (0.3 µM 
for 6hrs). ERK5 expression was assessed by western blotting. Unprenylation of Rap1A 
was measured as a control for simvastatin activity. The level of ERK5 activation 
assessed by mobility band shift was quantified and expressed as fold change relative to 
vehicle control (n=4) mean ± s.d. *P≤0.05, **P≤0.01 compared to vehicle control basal. 
(C) HCMECs were treated with GGTI-298 (10 µM)  for a range of time points. Intracellular 
signalling responses were assessed by western blotting for ERK5, unprenylated Rap1A 
and Rap1. (D) Immunofluorescence imaging of HCMEC tight junctions (ZO-1, green), 
actin stress fibres (phalloidin, red) and nuclei (Hoechst, Blue) following treatment with 
GGTI-298 (10 µM for 6hrs). Scale bars: 10 µm. (E) HCMEC were plated on Thincerts™ 
with 0.4µm pores and permeability of 4 kDa FITC-dextran across the HCMEC monolayer 
was assessed, (n=4), mean ± s.d. *P≤0.05 compared to vehicle control. 
  
 
Fig. 5.  MEK5 inhibition prevents simvastatin induced tight junction formation and 
ERK5 phosphorylation.  HCMECs were pre-incubated with BIX02189 1 µM for 30 
minutes priopr to addition of simvastatin 0.3 µM for 6hrs. (A) Immunofluorescence 
imaging of HCMEC tight junctions (ZO-1, green), actin stress fibres (phalloidin, red) and 
nuclei (Hoechst, blue). Scale bars: 10 µm. Results are from 1 experiment representative 
of 3. (B) Western blot of ZO-1, ERK5, phospho ERK5, unprenylated Rap1A and GAPDH 
levels in HCMECs. Level of ERK5 phosphorylation is quantified relative to vehicle control. 
Mean ± s.d. (n=3) *P≤0.05 compared to vehicle control basal. (C) Permeability of 4 kDa 
FITC-dextran through an endothelial monolayer on ThinCerts™, (n=4), mean ± s.d. 
*P≤0.05, **P≤0.01  compared to vehicle control. (D) Assessment of TEER was conducted 
on HCMECs plated on Thincerts™ containing 0.4µm pores, (n=4), mean ± s.d. **P≤0.01 
compared to vehicle control. (E) HCMECs were treated with simvastatin 0.3 µM for 6hrs 
before immunoprecipitation with IgG or ERK5 antibodies. Western blot of ZO-1 following 
immunoprecipitation with ERK5 in HCMECs. (F) Level of ZO-1 and ERK5 is quantified 
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relative to vehicle control in IP lysates. Mean ± s.d. (n=3). **P≤0.01, compared to vehicle 
control. 
  
Fig. 6. Simvastatin prevents doxorubicin induced barrier perturbment. HCMEC 
were pre-incubated with simvastatin 0.3 µM for 6hrs before treatment with doxorubicin 
0.1 µM for a further 6hrs. (A) Immunofluorescence imaging of HCMEC tight junctions 
(ZO-1, green), actin stress fibres (phalloidin, red) and nuclei (Hoechst, blue). Scale bars: 
10 µm. Results are from 1 experiment representative of 3. (B) Western blot of ZO-1, 
ERK5, ERK1/2, unprenylated Rap1A and Rap1 levels in HCMECs. Level of ERK5 
activation is quantified relative to vehicle control. Mean ± s.d. (n=3) **P≤0.01 compared 
to vehicle control. (C) HCMEC were plated on Thincerts™ with 0.4µm pores and 
permeability of 4 kDa FITC-dextran across the HCMEC monolayer was assessed and 
compared to vehicle control, (n=4), mean ± s.d. *P≤0.05, **P≤0.01  compared to vehicle 
control. (D) Assessment of TEER was conducted on HCMECs plated on Thincerts™ with 
0.4µm pores, (n=4), mean ± s.d. *P≤0.05, **P≤0.01 compared to vehicle control.  
   
Fig. 7. ERK5 and ZO-1 colocalise following simvastatin treatment in HCMECs. 
Immunofluorescence imaging of HCMEC tight junctions (ZO-1, green), ERK5 (red) and 
nuclei (Hoechst, blue) following treatment with simvastatin 0.3 µM and/or doxorubicin 0.1 
µM or BIX02189 1 µM for 6hrs. Scale bars: 10 µm. Arrows indicate co-localisation. 
Results are from 1 experiment representative of 3.  
 
Fig. 8. ERK5 cellular translocation following simvastatin treatment in HCMECs. 
HCMECs were treated with simvastatin 0.3 µM for 6hrs before subcellular fractionation 
performed. (A) Western blot of ZO-1 and ERK5. ATP1A1, actin and lamin B were used 
as positive controls to show cellular fraction specificity in membrane, cytoplasm and 
nuclear fractions respectively. Whole cell lysate (WCL). (B) Quantification of the total 
ERK5 level in each compartment (n=3), mean ± s.d. *P≤0.05 compared to vehicle control 
for each fraction. (C) Quantification of ERK5 band shift relative to each fraction’s vehicle 
control (n=3), mean ± s.d. *P≤0.05 compared to vehicle control for each fraction. 
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Supplementary Fig. Legends 
 
Supplementary Fig. 1. Statin induced ERK5 phosphorylation. HCMECs were 
incubated with (A) rosuvastatin and (B) pitavastatin at a range of concentrations for 6hrs. 
ERK5 phosphorylation was assessed by mobility band shift on western blotting. 
Unprenylation of Rap1A was measured as a control for statin activity.  
 
Supplementary Fig. 2.  Transporter expression in endothelial cells in comparison 
to the liver. Total RNA was isolated from HCMECs #1-3, HDMECs 1 & 2, HCAEC 1 & 
2, HBMEC, HUVEC, Liver 1 & 2 and mRNA levels were analysed by qRT-PCR for 
expression of SLCO1B1. (n=3), mean ± s.d. 
 
Supplementary Fig. 3.  Cell viability in response to doxorubicin in the presence 
and absence of simvastatin. (A) HCMECs, (B) A2780s and (C) BT474s were treated 
with doxorubicin alone and in the presence of simvastatin 0.3 µM for 72hrs. Cell viability 
was measured by Cell Titer Glo ATP assay. (D) IC50 levels were determined, mean ± s.d. 
(n=4), *P≤0.05 compared to doxrubicin alone, one-way ANOVA, SPSS.  
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